XML 39 R25.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 16 – SEGMENT INFORMATION

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the Chief Operating Decision Maker (“CODM”), or decision making group, in deciding how to allocate resources in assessing performance. The Company is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases and has one reportable segment. The Company’s CODM is the chief executive officer.

 

The accounting policies of the clinical-stage biopharmaceutical segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the clinical-stage biopharmaceutical segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss as consolidated net loss. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the chief operating decision maker and are reported on the consolidated statements of cash flows.

 

To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses while it seeks regulatory approval for pz-cel.

 

As such, the CODM uses cash forecast models in deciding how to invest into the clinical-stage biopharmaceutical segment. Such cash forecast models are reviewed to make decisions about allocating resources and assessing the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used to make decisions about allocating resources, assessing the performance of the segment and in establishing management’s compensation, along with cash forecast models.

 

 

The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:

 

 SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES

   2024   2023 
   For the year ended December 31, 
   2024   2023 
         
License and other revenues  $—   $3,500 
           
Research and development costs          
Salaries & related costs   15,345    11,373 
Non-cash stock-based compensation   1,561    1,086 
Other research and development costs (a)   17,454    18,632 
Total research and development costs   34,360    31,091 
           
General and administrative costs          
Salaries & related costs  $10,729   $6,942 
Non-cash stock-based compensation   5,067    3,682 
Pre-commercial preparation costs   4,818    1,224 
Other general and administrative costs (b)   9,237    7,156 
Total general and administrative costs  $29,851   $19,004 
           
Other segment items (c)   (477)   7,593 
Net loss  $(63,734)  $(54,188)

 

(a) Other research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and manufacturing facilities, and consultant-related expenses.
(b) Other general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.
(c) Other segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and other income.